Aclaris Therapeutics, Inc. - Common Stock (ACRS)

Competitors to Aclaris Therapeutics, Inc. - Common Stock (ACRS)

Aestu Medical

Aestu Medical specializes in developing non-invasive beauty treatments aimed at rejuvenating skin health and appearance. Their innovative approach towards skin technology competes directly with Aclaris's product lines that emphasize therapeutic dermatology. However, Aclaris holds a competitive advantage due to its established research capabilities and clinical data backing their products, which may provide greater trust and recognition among healthcare professionals.

NantKwest, Inc.

NantKwest operates in the immunotherapy space, focusing on cancer treatment, which overlaps with some of Aclaris's research initiatives in inflammatory conditions. Although Aclaris primarily targets dermatological diseases, both companies are engaged in developing advanced therapies that may utilize similar patient populations for skin-related side effects of systemic therapies. However, Aclaris's specific expertise in skin conditions gives it a nuanced edge within its specialized market segment.

Revance Therapeutics, Inc. 

Revance Therapeutics focuses on developing innovative therapies for aesthetic and therapeutic indications, particularly in the fields of dermatology and neurology. Their product, DaxibotulinumtoxinA injection, represents a direct competitive product in aesthetic procedures where Aclaris is also aiming to establish a footprint with its dermatological products. Furthermore, Revance's proprietary technology and long-lasting effects of their treatments may provide them with a competitive edge in patient preference and market capture.

Sientra, Inc.

Sientra offers a range of aesthetic products, including breast implants and body contouring, which indirectly compete with Aclaris’s dermatological and aesthetic treatments. While their core businesses are distinct, both companies target aesthetic outcomes, thus trying to capture the same demographic who may be looking for skin enhancing procedures. Aclaris’s focus on non-invasive dermatological treatment could be seen as a competitive advantage in this niche.